We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Smartphone-Based DNA Diagnostics Detects Malaria

By LabMedica International staff writers
Posted on 16 Aug 2021
There remains a substantial burden from infectious disease in low-resource rural communities, not least as a consequence of malaria. More...
In infectious disease diagnosis, results need to be communicated rapidly to healthcare professionals once testing has been completed so that care pathways can be implemented.

Diagnostic testing continues to underpin control and prevention strategies, primarily through the use of rapid, point-of-care, lateral flow immunoassays, which are affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable devices. This represents a particular challenge when testing in remote, low-resource rural communities, in which such diseases often create the largest burden.

Bioengineers at the University of Glasgow (Glasgow, UK) and their colleagues developed a smartphone-based end-to-end platform for multiplexed DNA diagnosis of malaria. The diagnostic platform comprises both hardware and software. The hardware includes a three-dimensional (3D) printed mobile heater for loop-mediated isothermal amplification (LAMP)-based diagnostics as well as a mobile phone and a low-cost disposable sensor cartridge, while the software includes an Arduino program, an Android app and a Hyperledger blockchain network.

The team field tested the platform on blood samples collected from 40 school children from Uganda, and compared their results with the gold-standard PCR assay. The team also used malaria rapid immunodiagnostic tests (RDT) for comparison.

The scientists reported that of the 28 tests that were correctly assigned and valid, 16 were true positives (positive for the manually recorded test, the blockchain records and real-time PCR), six were true negatives, three were false negatives and three were false positives (with respect to the gold standard). The blockchain implementation ensured the security of transactions, opening up the possibility for integration into surveillance databases, while maintaining the required safety around data privacy.

The authors concluded that the smartphone-based end-to-end platform they had developed for multiplexed DNA-based lateral flow diagnostic assays that can be used in remote, low-resource settings. Their decision support tool provides automated detection of the results and their analysis, supporting human expertise, and transactions involved in data handling are secured, trusted and endorsed using blockchain technology. The study was published on August 2, 2021 in the journal Nature Electronics.

Related Links:
University of Glasgow


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.